Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Nattokinase SHRANK arterial plaque by 36% with ZERO adverse effects. The study found 95.4% of patients taking 10,800 FU daily for 12 months experienced some degree of cardiovascular improvement. The 36% plaque reduction was verified using carotid artery ultrasound.

Nicolas Hulscher, MPH

282,981 subscribers

82,472 views • 6 days ago •via X (Twitter)

Science & Technology

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

A MAJOR study found nattokinase SHRANK arterial plaque by 36% with ZERO adverse effects. Among patients taking 10,800 FU daily for 12 months, 95.4% experienced some degree of cardiovascular improvement. The plaque reduction was objectively verified using carotid artery ultrasound. BB Maguire

A MAJOR study found nattokinase SHRANK arterial plaque by 36% with ZERO adverse effects. Among patients taking 10,800 FU daily for 12 months, 95.4% experienced some degree of cardiovascular improvement. The plaque reduction was objectively verified using carotid artery ultrasound. BB Maguire

Nicolas Hulscher, MPH

189,569 views • 1 month ago

Nattokinase can reduce arterial plaque by 36%. Joe Rogan was mind-blown talking to Michael Pollan about this supplement made from fermented soybeans (natto). It acts as a powerful natural clot-buster. High-dose nattokinase (around 10,800 FU/day) has been shown in clinical studies to reduce carotid artery plaque size by up to 36% and improve lipid profiles, with measurable results in as little as 12 months. A simple traditional fermented food might offer real cardiovascular benefits in a natural way. Have you tried nattokinase or any fermented foods for health reasons?

Nattokinase can reduce arterial plaque by 36%. Joe Rogan was mind-blown talking to Michael Pollan about this supplement made from fermented soybeans (natto). It acts as a powerful natural clot-buster. High-dose nattokinase (around 10,800 FU/day) has been shown in clinical studies to reduce carotid artery plaque size by up to 36% and improve lipid profiles, with measurable results in as little as 12 months. A simple traditional fermented food might offer real cardiovascular benefits in a natural way. Have you tried nattokinase or any fermented foods for health reasons?

Camus

68,005 views • 2 months ago

36% LESS artery plaque. That's what researchers reported after one year using 10,800 FU/day of nattokinase in over 1,000 participants. Too good to be true? I break down the entire study, the strengths, the weaknesses, and whether this changes how we should look at nattokinase. 👇

36% LESS artery plaque. That's what researchers reported after one year using 10,800 FU/day of nattokinase in over 1,000 participants. Too good to be true? I break down the entire study, the strengths, the weaknesses, and whether this changes how we should look at nattokinase. 👇

Marc Lobliner - IFBB Pro

291,831 views • 1 month ago

Nattokinase is truly a remarkable supplement. At 10,800 FU daily, it reverses arterial plague in 66.5% of patients over 12 months, with no side effects. The rest of the data is even more insane:

Nattokinase is truly a remarkable supplement. At 10,800 FU daily, it reverses arterial plague in 66.5% of patients over 12 months, with no side effects. The rest of the data is even more insane:

Dr. Biohacker

88,949 views • 2 months ago

Joe Rogan recently talked about a study involving 1,062 participants who took nattokinase for a full year. According to the reported ultrasound findings, arterial plaque was reduced by roughly 36%. The enzyme is said to help prevent new blockages while also supporting the reduction of existing plaque buildup. Here’s a closer look at the data and dosage protocol: (1/12)

Joe Rogan recently talked about a study involving 1,062 participants who took nattokinase for a full year. According to the reported ultrasound findings, arterial plaque was reduced by roughly 36%. The enzyme is said to help prevent new blockages while also supporting the reduction of existing plaque buildup. Here’s a closer look at the data and dosage protocol: (1/12)

Shadow Intel

75,600 views • 2 months ago

Joe Rogan recently discussed a study where 1,062 people took nattokinase for a year. Ultrasound results showed their arterial plaque actually shrank by 36%. This enzyme stops new blockages AND helps reverse the ones you already have. Let's look at the data and dosing: (1/12)

Joe Rogan recently discussed a study where 1,062 people took nattokinase for a year. Ultrasound results showed their arterial plaque actually shrank by 36%. This enzyme stops new blockages AND helps reverse the ones you already have. Let's look at the data and dosing: (1/12)

Patrick Sullivan Jr.

2,364,451 views • 5 months ago

Joe Rogan recently discussed a study where 1,062 people took nattokinase for a year. Ultrasound results showed their arterial plaque actually shrank by 36%. This enzyme stops new blockages AND helps reverse the ones you already have. Let's look at the data and dosing: (1/12)

Joe Rogan recently discussed a study where 1,062 people took nattokinase for a year. Ultrasound results showed their arterial plaque actually shrank by 36%. This enzyme stops new blockages AND helps reverse the ones you already have. Let's look at the data and dosing: (1/12)

Shadow Intel

305,240 views • 3 months ago

Dr. Ben Bikman says the evidence is "pretty solid” for Nattokinase, from the Japanese staple natto. The research is showing it might do much more than “just dissolving clots”. A published study following “a little over 1000 patients” with “confirmed carotid artery plaques” found “a significant reduction in plaque size”

Dr. Ben Bikman says the evidence is "pretty solid” for Nattokinase, from the Japanese staple natto. The research is showing it might do much more than “just dissolving clots”. A published study following “a little over 1000 patients” with “confirmed carotid artery plaques” found “a significant reduction in plaque size”

Humanspective

114,487 views • 5 months ago

Dr. Ovadia says nattokinase is something he routinely recommends as part of his protocol for patients. It a fibrinolytic agent, meaning it helps the body break down blood clots as they start to form. He points to a trial showing reduced arterial plaque in patients taking it, though that study measured carotid (neck) plaque rather than coronary plaque, which he flags as a caveat. As mentioned below, the trial tested 3,600 units daily (not statistically significant) versus 10,800 units daily (significant plaque reduction), so he typically suggests around 10,000 units a day. He cautions that many supplements are dosed too low or poorly sourced, and that anyone on blood-thinning medication should talk to their doctor first. (h/t Ken D Berry MD & DoctorTro)

Dr. Ovadia says nattokinase is something he routinely recommends as part of his protocol for patients. It a fibrinolytic agent, meaning it helps the body break down blood clots as they start to form. He points to a trial showing reduced arterial plaque in patients taking it, though that study measured carotid (neck) plaque rather than coronary plaque, which he flags as a caveat. As mentioned below, the trial tested 3,600 units daily (not statistically significant) versus 10,800 units daily (significant plaque reduction), so he typically suggests around 10,000 units a day. He cautions that many supplements are dosed too low or poorly sourced, and that anyone on blood-thinning medication should talk to their doctor first. (h/t Ken D Berry MD & DoctorTro)

A Paradise for Parents

115,917 views • 2 months ago

David Sinclair says he’s been reversing plaque in his arteries with nattokinase. On Peter Diamandis’ podcast, Sinclair shared that he’s been taking it for years and mentioned a Chinese study with 1,086 people that showed up to 95% plaque reduction in one year at sufficient doses (at least 12 fibrinolytic units daily). He also checks his own carotid arteries with ultrasound and says there’s no buildup. Nattokinase is an enzyme from fermented soybeans that breaks down fibrin. Some human studies show it can help reduce arterial plaque and improve blood flow, but results vary. Larger, high-quality trials are still limited, so it’s considered promising but not definitive. Cardiovascular disease is still the #1 killer. If there are accessible tools that support artery health beyond statins and lifestyle, it’s worth paying attention. Have you heard about nattokinase or tried anything similar for heart health?

David Sinclair says he’s been reversing plaque in his arteries with nattokinase. On Peter Diamandis’ podcast, Sinclair shared that he’s been taking it for years and mentioned a Chinese study with 1,086 people that showed up to 95% plaque reduction in one year at sufficient doses (at least 12 fibrinolytic units daily). He also checks his own carotid arteries with ultrasound and says there’s no buildup. Nattokinase is an enzyme from fermented soybeans that breaks down fibrin. Some human studies show it can help reduce arterial plaque and improve blood flow, but results vary. Larger, high-quality trials are still limited, so it’s considered promising but not definitive. Cardiovascular disease is still the #1 killer. If there are accessible tools that support artery health beyond statins and lifestyle, it’s worth paying attention. Have you heard about nattokinase or tried anything similar for heart health?

Camus

558,620 views • 2 months ago

$David Sinclair just revealed one of the biggest studies on nattokinase. A comprehensive Chinese study of 1,067 people found that nattokinase reversed cardiovascular disease by removing up to 95% of arterial plaque in one year. This supplement is an enzyme from fermented soybeans and costs almost nothing. Sinclair has been taking it daily for a couple of years. He measures his carotid artery with ultrasound and says there's no plaque buildup at all. Peter Diamandis takes it too. He believes you need at least 6,000 fibrinolytic units per day to reap the benefits. For context: • Statins cost hundreds per month and come with side effects. • Surgical interventions can cost thousands of dollars Nattokinase costs a fraction of both. Sinclair's caveat: "Do this with the knowledge of your physician." But the data exists. A study of over 1,000 people and up to 95% plaque removal in just 12 months. And the man whose lab is reversing aging takes it every day. — David Sinclair (David Sinclair) on Peter Diamandis' (Peter H. Diamandis, MD) Moonshots podcast PS. David Sinclair is speaking at SynBioBeta on May 6th this year, discussing the science of slowing and reversing aging. If longevity is the world you're in, the investors, partners, and scientists shaping this space will be in the room. Grab your ticket in the comments below.$

David Sinclair just revealed one of the biggest studies on nattokinase. A comprehensive Chinese study of 1,067 people found that nattokinase reversed cardiovascular disease by removing up to 95% of arterial plaque in one year. This supplement is an enzyme from fermented soybeans and costs almost nothing. Sinclair has been taking it daily for a couple of years. He measures his carotid artery with ultrasound and says there's no plaque buildup at all. Peter Diamandis takes it too. He believes you need at least 6,000 fibrinolytic units per day to reap the benefits. For context: • Statins cost hundreds per month and come with side effects. • Surgical interventions can cost thousands of dollars Nattokinase costs a fraction of both. Sinclair's caveat: "Do this with the knowledge of your physician." But the data exists. A study of over 1,000 people and up to 95% plaque removal in just 12 months. And the man whose lab is reversing aging takes it every day. — David Sinclair (David Sinclair) on Peter Diamandis' (Peter H. Diamandis, MD) Moonshots podcast PS. David Sinclair is speaking at SynBioBeta on May 6th this year, discussing the science of slowing and reversing aging. If longevity is the world you're in, the investors, partners, and scientists shaping this space will be in the room. Grab your ticket in the comments below.

John Cumbers

841,337 views • 4 months ago

The rare moment in longevity talk is a Harvard professor admitting the study is imperfect and still swallowing the capsule. Sinclair is taking nattokinase because a Chinese cohort of about a thousand people showed carotid plaque and IMT moving in the right direction. Natto is fermented soy eaten by Bacillus subtilis. The enzyme can break fibrin. He takes about 10,000 fibrinolytic units in the morning, then wants the next carotid ultrasound to keep score. That matters because most supplement talk never names a dose or a readout. IMT is imperfect, but it is a number a clinic can actually take. Short science, so this does not float as folklore: the signal people cite is largely Chen et al., Front. Cardiovasc. Med. 2022 — open-label, roughly 1,062 adults, 10,800 FU per day for 12 months. A smaller head-to-head used 6,000 FU/day for 26 weeks. Sinclair’s own figure is ~10,000 FU each morning. A separate multi-year carotid RCT at a lower dose did not copy the plaque drop. The enzyme is fibrinolytic, so it is a conversation with a doctor if you already use blood thinners. Food-dose natto is not the same claim as “this melts arteries.” Collecting bottles is easy. Naming the units and asking the vessel wall to answer is the part that still looks like science.

The rare moment in longevity talk is a Harvard professor admitting the study is imperfect and still swallowing the capsule. Sinclair is taking nattokinase because a Chinese cohort of about a thousand people showed carotid plaque and IMT moving in the right direction. Natto is fermented soy eaten by Bacillus subtilis. The enzyme can break fibrin. He takes about 10,000 fibrinolytic units in the morning, then wants the next carotid ultrasound to keep score. That matters because most supplement talk never names a dose or a readout. IMT is imperfect, but it is a number a clinic can actually take. Short science, so this does not float as folklore: the signal people cite is largely Chen et al., Front. Cardiovasc. Med. 2022 — open-label, roughly 1,062 adults, 10,800 FU per day for 12 months. A smaller head-to-head used 6,000 FU/day for 26 weeks. Sinclair’s own figure is ~10,000 FU each morning. A separate multi-year carotid RCT at a lower dose did not copy the plaque drop. The enzyme is fibrinolytic, so it is a conversation with a doctor if you already use blood thinners. Food-dose natto is not the same claim as “this melts arteries.” Collecting bottles is easy. Naming the units and asking the vessel wall to answer is the part that still looks like science.

Camus

31,090 views • 5 days ago

The Keto + LDL study is making waves online—but what did it really show? In this video, Dr. Matthew Budoff, principal investigator from UCLA’s Lundquist Institute, breaks down the findings behind the headlines. While social media has the tendency to rush to simplify the results of a complex study like this, here is what is important to know: 🫀 The study did observe plaque progression in Lean Mass Hyper-Responders. 📊 LDL and Apo-B were not predictive of the amount of plaque progression but baseline plaque was Thus the results do not imply that LMHRs are at a zero risk for plaque progression. But determining how much of a risk depends on understanding the exact measurement techniques used in the study. Stay tuned for upcoming videos exploring the nuances of measurement techniques, data interpretation, and cardiovascular risk in this unique population. 🎧 Listen to the full interview with Dr. Budoff here:

The Keto + LDL study is making waves online—but what did it really show? In this video, Dr. Matthew Budoff, principal investigator from UCLA’s Lundquist Institute, breaks down the findings behind the headlines. While social media has the tendency to rush to simplify the results of a complex study like this, here is what is important to know: 🫀 The study did observe plaque progression in Lean Mass Hyper-Responders. 📊 LDL and Apo-B were not predictive of the amount of plaque progression but baseline plaque was Thus the results do not imply that LMHRs are at a zero risk for plaque progression. But determining how much of a risk depends on understanding the exact measurement techniques used in the study. Stay tuned for upcoming videos exploring the nuances of measurement techniques, data interpretation, and cardiovascular risk in this unique population. 🎧 Listen to the full interview with Dr. Budoff here:

Metabolic Mind

65,039 views • 1 year ago

What if everything we thought we knew about cholesterol and heart disease risk… doesn’t apply to everyone? In this episode, world-renowned cardiologist Dr. Matthew Budoff unpacks the results of a landmark one-year study tracking 100 lean, metabolically healthy individuals on a ketogenic diet with extremely elevated LDL levels. Dr. Budoff is the Program Director, Director of Cardiac CT, and the endowed chair of preventive cardiology at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. In this interview, Dr. Scher and Dr. Budoff further break down the results of his new publication, which used advanced imaging to demonstrate that LDL cholesterol and ApoB levels are not associated with plaque progression in Lean-Mass Hyper Responders following a #ketogenicdiet. 📊 Surprising insights: • Elevated LDL and ApoB did not predict plaque progression • Some participants with LDLs over 500 showed no plaque at all • A few participants even experienced plaque regression • Existing plaque—not LDL-C or ApoB—did predict plaque accumulation in this population Dr. Budoff explains what these results mean for clinicians, for patients using ketogenic therapy as a medical intervention, and for the broader conversation around cardiovascular disease risk. “It is important that clinicians, along with the general public, are made aware that personalized, data-driven approaches to assessing risk should be considered based on individual conditions,” said Dr. Budoff. “The existence of this phenotype suggests that alternative markers or tests should be used to establish metabolic health in some cases.” 🎬 These exciting new findings are featured in Dave Feldman and Jen Isenhart’s upcoming documentary, The Cholesterol Code, the story of how a software engineer conducts a groundbreaking study on an unusual group of people—lean, healthy individuals whose doctors are convinced they’ll die young. Real stories of healing with ketogenic diets provide a blueprint for using food as powerful medicine. Visit to learn more about the film and to be the first to hear about private screenings and the general release in the fall. Expert Featured: Dr. Matthew Budoff Matthew Budoff MD Resources Mentioned: Plaque Begets Plaque, ApoB Does Not Diagnostic and Preventative Cardiovascular Imaging Center CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Learn more about metabolic psychiatry and find helpful resources at

What if everything we thought we knew about cholesterol and heart disease risk… doesn’t apply to everyone? In this episode, world-renowned cardiologist Dr. Matthew Budoff unpacks the results of a landmark one-year study tracking 100 lean, metabolically healthy individuals on a ketogenic diet with extremely elevated LDL levels. Dr. Budoff is the Program Director, Director of Cardiac CT, and the endowed chair of preventive cardiology at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. In this interview, Dr. Scher and Dr. Budoff further break down the results of his new publication, which used advanced imaging to demonstrate that LDL cholesterol and ApoB levels are not associated with plaque progression in Lean-Mass Hyper Responders following a #ketogenicdiet. 📊 Surprising insights: • Elevated LDL and ApoB did not predict plaque progression • Some participants with LDLs over 500 showed no plaque at all • A few participants even experienced plaque regression • Existing plaque—not LDL-C or ApoB—did predict plaque accumulation in this population Dr. Budoff explains what these results mean for clinicians, for patients using ketogenic therapy as a medical intervention, and for the broader conversation around cardiovascular disease risk. “It is important that clinicians, along with the general public, are made aware that personalized, data-driven approaches to assessing risk should be considered based on individual conditions,” said Dr. Budoff. “The existence of this phenotype suggests that alternative markers or tests should be used to establish metabolic health in some cases.” 🎬 These exciting new findings are featured in Dave Feldman and Jen Isenhart’s upcoming documentary, The Cholesterol Code, the story of how a software engineer conducts a groundbreaking study on an unusual group of people—lean, healthy individuals whose doctors are convinced they’ll die young. Real stories of healing with ketogenic diets provide a blueprint for using food as powerful medicine. Visit to learn more about the film and to be the first to hear about private screenings and the general release in the fall. Expert Featured: Dr. Matthew Budoff Matthew Budoff MD Resources Mentioned: Plaque Begets Plaque, ApoB Does Not Diagnostic and Preventative Cardiovascular Imaging Center CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

10,423 views • 1 year ago

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

98,147 views • 1 year ago

We found 84% of cancer patients taking ivermectin and mebendazole for 6 months declared their cancer was either COMPLETELY GONE, REGRESSED, or STOPPED SPREADING. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

We found 84% of cancer patients taking ivermectin and mebendazole for 6 months declared their cancer was either COMPLETELY GONE, REGRESSED, or STOPPED SPREADING. It’s no surprise the CIA BURIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer growth.

Nicolas Hulscher, MPH

2,386,810 views • 4 months ago

We found 84% of cancer patients taking ivermectin and mebendazole declared their cancer was either COMPLETELY GONE, SHRUNK, or STOPPED SPREADING after 6 months. This explains why the CIA CLASSIFIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer.

We found 84% of cancer patients taking ivermectin and mebendazole declared their cancer was either COMPLETELY GONE, SHRUNK, or STOPPED SPREADING after 6 months. This explains why the CIA CLASSIFIED a 1950s study for over HALF A CENTURY showing anti-parasitics disrupt cancer.

Nicolas Hulscher, MPH

75,733 views • 4 months ago

This should be front-page news EVERYWHERE. The LARGEST real-world study of ivermectin + mebendazole in cancer patients found that nearly HALF declared CANCER DISAPPEARANCE or TUMOR SHRINKAGE after just 6 months. 84.4% experienced clinical benefit. This was not surprising, as HUNDREDS of preclinical studies have shown anti-parasitics attack tumors via 12 distinct mechanisms across more than 12 cancer types. Brad Smith

This should be front-page news EVERYWHERE. The LARGEST real-world study of ivermectin + mebendazole in cancer patients found that nearly HALF declared CANCER DISAPPEARANCE or TUMOR SHRINKAGE after just 6 months. 84.4% experienced clinical benefit. This was not surprising, as HUNDREDS of preclinical studies have shown anti-parasitics attack tumors via 12 distinct mechanisms across more than 12 cancer types. Brad Smith

Nicolas Hulscher, MPH

19,219 views • 4 months ago

Can you actually reverse heart disease, or just slow it down? Eighteen months after a scan found soft plaque in my arteries, a follow-up suggested it had shrunk by around forty percent, and I wanted to know whether that result could be trusted. In this episode, I sit down with interventional cardiologist Dr Campbell Rogers to unpack what modern imaging can really see, why a calcium score of zero is not the all-clear, and whether we should be treating plaque rather than chasing a number. For the full show notes head to:

Can you actually reverse heart disease, or just slow it down? Eighteen months after a scan found soft plaque in my arteries, a follow-up suggested it had shrunk by around forty percent, and I wanted to know whether that result could be trusted. In this episode, I sit down with interventional cardiologist Dr Campbell Rogers to unpack what modern imaging can really see, why a calcium score of zero is not the all-clear, and whether we should be treating plaque rather than chasing a number. For the full show notes head to:

Simon Hill MSc, BSc

23,435 views • 1 month ago

This is nothing short of a miracle. Dr John Campbell breaks down the study of an 83yr old woman with stage 4 breast cancer that had metastasised to the liver, spine and bones. Usually a death sentence. She took a daily dose of 222mg of FenBen for 8 months. Which normalised her liver enzymes. The tumor marker dropped from 316 to 36. There was an absence of any abnormal metabolic activity indicative of cancer.

This is nothing short of a miracle. Dr John Campbell breaks down the study of an 83yr old woman with stage 4 breast cancer that had metastasised to the liver, spine and bones. Usually a death sentence. She took a daily dose of 222mg of FenBen for 8 months. Which normalised her liver enzymes. The tumor marker dropped from 316 to 36. There was an absence of any abnormal metabolic activity indicative of cancer.

Kat A 🌸

1,058,201 views • 9 months ago